|
1
|
Chao CL, Kuo HP, Huang HW, Cheng MY, Chao HF, Lu SM, Lin HC, Wang CJ, Chang TC, Wu CR. Poria cocos Lanostane Triterpenoids Extract Promotes Collagen and Hyaluronic Acid Production in D-Galactose-Induced Aging Rats. Life (Basel) 2023; 13:2130. [PMID: 38004270 PMCID: PMC10672192 DOI: 10.3390/life13112130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 10/18/2023] [Accepted: 10/24/2023] [Indexed: 11/26/2023] Open
Abstract
The global aging population is expanding at an increasingly rapid pace, with approximately one-fourth of the world's population expected to be composed of elderly individuals by 2050. Aging skin is one of the major characteristics expressed in the elderly. The study comprehensively utilizes both cell and animal experiments to confirm the skin anti-aging effects of Poria cocos (P. cocos), which is one of the most important traditional Chinese medicines classified as tonic Chinese medicine, commonly used to treat physical weakness and aging-associated diseases. We demonstrate in this study that P. cocos lanostane triterpenoids extract (Lipucan®) ameliorates aging skin and promotes collagen accumulation and hyaluronic acid production in galactose-induced aging rats. Purified lanostane triterpenoids were initially identified as active components in P. cocos, which significantly increased collagen and hyaluronic acid levels in cultured human skin cells.
Collapse
Affiliation(s)
- Chien-Liang Chao
- Sinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan; (C.-L.C.); (H.-W.H.); (M.-Y.C.); (H.-F.C.); (S.-M.L.); (H.-C.L.)
| | - Han-Peng Kuo
- SynCore Biotechnology Co., Ltd., Sinphar Group, Yilan 269, Taiwan;
| | - Hsin-Wen Huang
- Sinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan; (C.-L.C.); (H.-W.H.); (M.-Y.C.); (H.-F.C.); (S.-M.L.); (H.-C.L.)
| | - Maw-Yeun Cheng
- Sinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan; (C.-L.C.); (H.-W.H.); (M.-Y.C.); (H.-F.C.); (S.-M.L.); (H.-C.L.)
| | - Hsin-Fan Chao
- Sinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan; (C.-L.C.); (H.-W.H.); (M.-Y.C.); (H.-F.C.); (S.-M.L.); (H.-C.L.)
| | - Shih-Min Lu
- Sinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan; (C.-L.C.); (H.-W.H.); (M.-Y.C.); (H.-F.C.); (S.-M.L.); (H.-C.L.)
| | - Hang-Ching Lin
- Sinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan; (C.-L.C.); (H.-W.H.); (M.-Y.C.); (H.-F.C.); (S.-M.L.); (H.-C.L.)
- School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan
| | - Chao-Jih Wang
- Sinphar Tian-Li Pharmaceutical Co., Ltd., Sinphar Group, Hangzhou 311100, China;
| | - Tsu-Chung Chang
- Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan
| | - Chi-Rei Wu
- Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan
| |
Collapse
|